Inhaled Insulin Gets India Go-Ahead – KOLs Assess Role

 
• By Anju Ghangurde

Cipla secures regulatory approval for partner MannKind’s Afrezza following a Phase III trial in India. KOLs signal nuanced enthusiasm for the inhaled insulin which is approved in the US and Brazil.

Inhaled Insulin Heads For India Debut

More from Business

More from Deals